肺癌表皮生长因子受体酪氨酸激酶抑制剂获得性耐药的逆转

doi:10.3760/cma.j.issn.1673-422X.2013.11.013

摘要/Abstract

摘要： 以表皮生长因子受体（EGFR）为靶点治疗非小细胞肺癌是治疗肺癌的前沿手段，其产生的获得性耐药限制了靶向药物的发展。目前已有大量的有关EGFR突变耐药的数据，利用这些数据，人们正在探讨克服EGFR靶向治疗耐药的3个基本方法：强化EGFR的抑制、EGFR抑制剂与其他靶向治疗相结合以及通过替代途径改变抗癌治疗方法。

关键词: 肺肿瘤, 受体, 表皮生长因子, 抗药性, 抑制剂

Abstract: Epidermal growth factor receptor (EGFR) inhibitors targeted therapy is the forward position means for nonsmall cell lung cancer. However, acquired resistance to EGFR inhibitors limits the development of targeted drugs. Using existing data on drug resistance in EGFRmutant lung cancer, this review discusses three basic approaches for overcoming resistance to EGFRtargeted therapies: intensification of EGFR inhibition, combination of EGFR inhibitors with other targeted therapies, and altering clinical management via alternate pathways.

Key words: Lung neoplasms, Receptor, epidermal growth factor, Drug resistance, Inhibitors

李辰晨, 冯继锋. 肺癌表皮生长因子受体酪氨酸激酶抑制剂获得性耐药的逆转[J]. 国际肿瘤学杂志, 2013, 40(11): 843-846.

LI Chen-Chen, FENG Ji-Feng. Reversal for acquired resistance to EGFR inhibitors in lung cancer[J]. Journal of International Oncology, 2013, 40(11): 843-846.

参考文献

［1］ Heist RS, Christiani D. EGFR-targeted therapies in lung cancer: predictors of response and toxicity. Pharmacogenomics, 2009, 10(1):59-68. ［2］ Oxnard GR, Arcila ME, Chmielecki J, et al. New strategies in overcoming acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer. Clin Cancer Res, 2011, 17(17):5530-5537. ［3］ Oxnard GR. Strategies for overcoming acquired resistance to epidermal growth factor receptortargeted therapies in lung cancer. Arch Pathol Lab Med, 2012, 136(10):1205-1209. ［4］ Keedy VL, Temin S, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol, 2011, 29(15):2121-2127. ［5］ Onitsuka T, Uramoto H, Nose N, et al. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET and HGF status. Lung Cancer, 2010, 68(2): 198-203. ［6］乔建兵，陈文萍. 酪氨酸激酶抑制剂耐药机制及其治疗策略. 中国肺癌杂志, 2011, 14(10):806-810. ［7］ GodinHeymann N, Ulkus L, Brannigan BW, et al. The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol Cancer Ther, 2008, 7(4):874-879. ［8］ Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA, 2008, 105(6):2070-2075. ［9］ Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib,gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol, 2012, 13(5):528-538. ［10］ Zhou W, Ercan D, Chen L, et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature, 2009, 462(7276):1070-1074. ［11］ Janjigian YY, Groen HJM, Horn L, et al. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. J Clin Oncol, 2011, 29(15 Suppl):7525. ［12］ Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med, 2011, 3(75):75ra26. ［13］ Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med, 2008, 14(12):1351- 1356. ［14］ Chaft JE, Arcila ME, Paik PK, et al. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinomarationale for comprehensive mutation profiling. Mol Cancer Ther, 2012, 11(2):485-491. ［15］ Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistanceto EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res, 2013, 19(8):2240-2247. ［16］尹威民，王旭，于明霞，等. 肺癌EGFR突变的TKI靶向治疗耐药机制研究进展. 中国老年学杂志, 2011, 31(11): 2136-2138. ［17］ Choi Y, Rho J, Jeon BS, et al. Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors. Cancer Chemother Pharmacol, 2010, 66(2):381-388. ［18］ Wu JY, Shih JY, Yang CH, et al. Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer. Int J Cancer, 2010, 126(1):247-255. ［19］ Shimamura T, Li D, Ji H, et al. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res, 2008, 68(14):5827-5838. ［20］ Bivona TG, Hieronymus H, Parker J, et al. FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Nature, 2011, 471(7339):523-526. ［21］ Yatabe Y, Matsuo K, Mitsudomi T. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol, 2011, 29(22):2972-2977. ［22］ Chmielecki J, Foo J, Oxnard GR, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med, 2011, 3(90):90ra59. ［23］ Chaft JE, Oxnard GR, Sima CS, et al. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib. Clin Cancer Res, 2011, 17(19):6298-6303. ［24］ Oxnard GR, Arcila ME, Sima CS, et al. Acquired resistanceto EGFR tyrosine kinase inhibitors in EGFR-mutantlung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res, 2011, 17(6):1616-1622.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[3]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[4]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[5]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[6]	钟楠, 王淡瑜, 周欢欢, 刘宁, 戴纬, 刘黎琼, 郭智. CD30单抗联合PD-1抑制剂治疗复发难治性霍奇金淋巴瘤的疗效与安全性[J]. 国际肿瘤学杂志, 2024, 51(4): 245-248.
[7]	钱晓涛, 石子宜, 胡格. Ⅲ~ⅣA期食管鳞状细胞癌根治性放化疗后行免疫检查点抑制剂维持治疗的真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(3): 151-156.
[8]	解淑萍, 孙亚红, 汪超. 早期肿瘤标志物联合NLR、PLR预测胃癌免疫治疗疗效[J]. 国际肿瘤学杂志, 2024, 51(3): 157-165.
[9]	龚艳, 陈洪雷. 微RNA调控卵巢癌顺铂耐药的机制研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 186-190.
[10]	滕远, 李莉娟, 张连生. MCL-1及其抑制剂在血液恶性肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 119-122.
[11]	贺嘉慧, 胡钦勇. 基于GBD数据的中国和美国肺癌发病和死亡趋势及危险因素对比分析[J]. 国际肿瘤学杂志, 2024, 51(1): 29-36.
[12]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[13]	陈欣祎, 翁一鸣, 魏家燕, 王劲松, 彭敏. 免疫检查点抑制剂在复发或转移性头颈部鳞状细胞癌治疗中的进展[J]. 国际肿瘤学杂志, 2023, 50(9): 553-557.
[14]	邓隽军, 赵大勇, 李淼. 免疫检查点抑制剂在非小细胞肺癌治疗中的不良反应及危险因素[J]. 国际肿瘤学杂志, 2023, 50(9): 564-568.
[15]	黄辉, 丁江华. 靶向FGFR2治疗晚期胆管癌的研究进展[J]. 国际肿瘤学杂志, 2023, 50(9): 569-573.